Every 10-Q that Silexion Therapeutics Corp (SLXN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLXN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLXN filings page.
Silexion Therapeutics Corp is a clinical-stage biotech focused on RNAi therapies for KRAS-driven cancers, led by SIL204 for locally advanced pancreatic cancer. Regulatory approvals in Israel and Germany allow a Phase 2/3 trial, with first site in Tel Aviv activated shortly after quarter-end.
For the six months ended June 30, 2026, Silexion reported a net loss of $6.3 million (up from $4.2 million), driven by higher R&D expenses of $3.6 million and G&A of $2.8 million. Cash and cash equivalents were $2.2 million, total assets $4.2 million, and shareholders’ equity only $44 thousand. Operating cash outflow was $6.6 million, and the company discloses substantial doubt about its ability to continue as a going concern, estimating its current funds cover only several months.
To fund operations, Silexion relies on dilutive equity financings, including public offerings, induced warrant exercises, and an at-the-market program under which about $2.0 million (net) was raised in the first half of 2026 and an additional $0.3 million thereafter. A related-party promissory note was partly converted to equity. After an August 2026 offering and other transactions, pro forma shareholders’ equity is described as approximately $3.2 million, restoring compliance with Nasdaq’s $2.5 million equity requirement, but the company remains dependent on continued market access and has recently executed multiple reverse share splits to support its listing and financing capacity.
Silexion Therapeutics Corp reports a wider net loss as it funds its KRAS-targeted RNAi cancer pipeline. For the three months ended March 31, 2026, net loss rose to $2.7M from $1.7M a year earlier, driven by higher research and development spending of $1.4M versus $0.6M, mainly for toxicology work, product development and trial preparation. General and administrative expenses increased to $1.4M from $1.1M, reflecting professional services and share-based compensation for directors and executives.
Cash and cash equivalents fell to $2.4M at March 31, 2026 from $6.0M at December 31, 2025, with operating activities using $3.6M of cash in the quarter. Shareholders’ equity declined sharply to $0.3M from $2.6M, prompting management to conclude there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity, Silexion raised modest funds under an at-the-market facility in the quarter and, after quarter-end, completed a large warrant exercise inducement and additional ATM sales, and increased its authorized share capital. Shareholders also approved a 1-for-10 reverse share split intended to support continued Nasdaq listing and future capital-raising.
Silexion Therapeutics Corp (SLXN) filed its quarterly report detailing continued operating losses and new financing capacity. For the nine months ended September 30, 2025, the company reported a net loss of $7.5 million on operating expenses of $7.2 million. Cash and cash equivalents increased to $9.243 million as of September 30, 2025, up from $1.187 million at year‑end, driven by equity raises and warrant exercises.
The balance sheet shifted to shareholders’ equity of $6.977 million from a deficit at December 31, 2024. During 2025, the company completed public offerings with aggregate gross proceeds of approximately $5.0 million in January and $6.0 million in September, plus additional gross proceeds from warrant exercises, including $1.78 million tied to September warrants. It also established an ATM program up to $13.17 million and has an effective S‑3 shelf up to $100 million.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern given ongoing losses and expected negative operating cash flows. Reverse share splits of 1‑for‑9 and 1‑for‑15 were effected in November 2024 and July 2025, respectively. Shares outstanding were 3,126,642 as of November 9, 2025.
Silexion Therapeutics Corp (SLXN) is a clinical-stage biotech developing SIL204, a second-generation siRNA targeting mutant KRAS in oncology. The company reported a net loss of $4.238 million for the six months ended June 30, 2025 and had $3.466 million of cash and cash equivalents on hand at that date. Operating cash outflow for the six months was $4.96 million and the accumulated deficit was $47.5 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern for 12 months without additional financing.
The company completed equity financings in January 2025 (gross proceeds ~$5.0 million) and inducement warrant exercises raising ~$3.276 million through June 30, 2025, and used an equity line of credit (ELOC) raising an aggregate of $3.1 million through June 30, 2025. Nasdaq trading and listing matters required two reverse share splits (1-for-9 and 1-for-15) and the company received a hearings panel decision allowing continued listing subject to a compliance plan to reach $2.5 million of shareholders equity by September 19, 2025.